| Literature DB >> 21329652 |
Guan Jiang1, Zhi-Ping Wei, Dong-Sheng Pei, Yong Xin, Yan-Qun Liu, Jun-Nian Zheng.
Abstract
Malignant glioma is the most common primary brain tumor. Malignant melanoma is the most malignant of skin tumor. The two malignancies are poorly responsive to conventional treatment regimens such as chemotherapy. Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma. Resistance to alkylating agents such as TMZ correlates with increased expression of DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). Several studies in animal models have demonstrated that decreasing MGMT level with gene therapy could overcome TMZ resistance and enhance tumor cell death. In the present review, we provide an overview of recent advances in this field.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21329652 DOI： 10.1016/j.bbrc.2011.02.042
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN： 0006-291X Impact factor: 3.575